John J. Orloff — Executive VP and Head of Research & Development at Alexion Pharmaceuticals

Dr. John J. Orloff, M.D., has been an Executive Vice President and Head of Research & Development at Alexion Pharmaceuticals, Inc. since June 5, 2017. Dr. Orloff focused on strengthening the Alexion's clinical pipeline and research programs, enhancing R&D productivity, overseeing regulatory and medical affairs and supporting business development. Dr. Orloff's experience in successfully developing biopharmaceuticals, including in the areas of hematology, immunology and metabolics, as well his strong global clinical and regulatory expertise, makes him ideally suited to lead the R&D function at Alexion. Dr. Orloff has been Executive Vice President and Head of Research & Development at Aegerion Pharmaceuticals, Inc. since November 3, 2016. In this role, Dr. Orloff oversees the effort to build a nimble development organization to advance its portfolio of products for rare diseases, including the design of a clinical program for MYALEPT with the goal of developing it to its full potential. Dr. Orloff served as Head of Research & Development and Executive Vice President of Novelion Therapeutics Inc. since November 2016 until June 5, 2017. He has more than 30 years of global experience in industry, clinical, drug discovery and development. He served as Chief Scientific Officer, Global Head of Research & Development and Executive Vice President at Baxalta Incorporated, where he advanced its pipeline and oversaw regulatory approval of 10 unique products and two devices over two years. Dr. Orloff is a global R&D business leader with 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. He was responsible for advancing Baxalta's pipeline across hematology, immunology and oncology. He served as Global Head of Research & Development and Vice President at Baxter BioScience Inc., since joining in July 2014. He was responsible for advancing the late-stage BioScience pipeline, enhancing the R&D operating model and additional innovative opportunities for the business. Dr. Orloff served as Vice President for Clinical Development and Medical Affairs at the Novartis business franchise for Arthritis, Bone and Women's Health of Novartis AG. He served as Global Head of Clinical Development and Senior Vice President at Merck Serono Pharmaceuticals. From 2003 to 2013, he held a series of scientific leadership roles at Novartis Pharma AG. Dr. Orloff served as Chief Medical Officer and Senior Vice President of Global Development for Novartis Pharma AG where he led the Trials of the Future initiative to get innovation to the drug development process. He also served as Head of U.S. Medical and Drug Regulatory Affairs for North America. He was a senior director at Merck Research Laboratories, where he began as an associate director in 1997. Dr. Orloff supported clinical development at Merck Research Labs and was previously a faculty member at the Yale University School of Medicine for seven years. his expertise in bone biology contributed to marketing approvals for treatments for a range of bone disorders and he has led programs across a diverse range of therapeutic areas, including immunology, neurology and oncology. He has been Director of Novelion Therapeutics Inc. since July 1, 2017. He has been a Member of Innovation Advisory Board at Mytrus, Inc., since March 18, 2014. Dr. Orloff completed his internal medicine residency at University of Pittsburgh Medical Center and his endocrinology and metabolism fellowship at Yale University School of Medicine. He holds an M.D. from University of Vermont College of Medicine and a B.A. in chemistry from Dartmouth College.